Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,906,945 shares of the specialty pharmaceutical company’s stock after selling 183,927 shares during the quarter. Vanguard Group Inc. owned 9.74% of Jazz Pharmaceuticals worth $778,535,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LSV Asset Management grew its position in Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after purchasing an additional 87,576 shares during the period. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after acquiring an additional 145,865 shares during the period. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals in the second quarter valued at approximately $127,344,000. Finally, Geode Capital Management LLC boosted its position in Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $124,366,000 after purchasing an additional 16,757 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 84,398 shares of company stock worth $14,957,430. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Up 1.5%

JAZZ stock opened at $172.19 on Monday. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99. The business’s 50-day moving average is $167.92 and its 200 day moving average is $149.40. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. The stock has a market cap of $10.46 billion, a price-to-earnings ratio of -28.37, a PEG ratio of 0.93 and a beta of 0.26.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. JPMorgan Chase & Co. cut their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday, November 17th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.